Company Information

D-Kimia develops novel diagnostic solutions to detect a broad range of diseases by targeting the nucleic acid signature of the disease. Our diagnostic solutions are rapid, affordable, simple to use, and provide the same level of specificity as the most advanced Polymerase Chain Reaction (PCR), and other amplification- based diagnostic techniques.
D-Kimia develops nano-particle based diagnostic solutions to detect a broad range of diseases by targeting the nucleic acid signature of the disease. Our diagnostic solutions are rapid, affordable, simple to use, and provide the same level of specificity as the most advanced Polymerase Chain Reaction (PCR), and other amplification- based diagnostic techniques. The Hepatitis C Virus (HCV) infects over 170 million people worldwide and continues to spread across the globe. D-Kimia’s patent pending platform has initially been optimized for the identification of the Hepatitis C virus. Our assay offers rapid, accurate, and affordable molecular detection of HCV without expensive and complicated lab equipment. D-Kimia is further developing its diagnostic platform to identify the nucleic acid signature of a range of viruses and genetic disease markers including tuberculosis, malaria, breast cancer and bladder cancer.


Business Type N/A

Linked Institutions N/A

Primary Industry N/A

Date Founded 01/2013

Founders N/A

Team Members N/A

Development Stage N/A

Revenue Generating No


Demographics

Headquarters: Login to unlock

Branches: Login to unlock

Sub-Industries: Login to unlock

Industries: Login to unlock

Geographical Focus: Login to unlock